Literature DB >> 20542985

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Duck Cho1, David R Shook, Noriko Shimasaki, Yu-Hsiang Chang, Hiroyuki Fujisaki, Dario Campana.   

Abstract

PURPOSE: To develop new therapies for children with solid tumors, we tested the cytotoxicity of natural killer (NK) cells expanded by coculture with K562-mb15-41BBL cells. We sought to identify the most sensitive tumor subtypes, clarify the molecular interactions regulating cytotoxicity, and determine NK antitumor potential in vivo. EXPERIMENTAL
DESIGN: We tested in vitro cytotoxicity of expanded NK cells against cell lines representative of Ewing sarcoma (EWS; n = 5), rhabdomyosarcoma (n = 4), neuroblastoma (n = 3), and osteosarcoma (n = 3), and correlated the results with expression of inhibitory and activating NK receptor ligands. We also compared expanded and primary NK cells, determined the effects of activating receptor ligation and of chemotherapeutic drugs, and assessed the therapeutic effect of NK cell infusions in xenografts.
RESULTS: In 45 experiments, EWS and rhabdomyosarcoma cell lines were remarkably sensitive to expanded NK cells, with median cytotoxicities at 1:1 effector/target ratio of 87.2% and 79.1%, respectively. Cytotoxicity was not related to levels of expression of NK receptor ligands, nor was it affected by pretreatment of target cells with daunorubicin or vincristine, but was markedly inhibited by preincubation of NK cells with a combination of antibodies against the NK-activating receptors NKGD2 and DNAM-1. Expanded NK cells were considerably more cytotoxic than unstimulated NK cells, and eradicated EWS cells engrafted in nonobese diabetic/severe combined immunodeficient Il2rgnull mice.
CONCLUSIONS: Among pediatric solid tumors, EWS and rhabdomyosarcoma are exquisitely sensitive to expanded NK cells. The NK expansion method described here has been adapted to large-scale conditions and supports a phase I clinical study including patients with these malignancies. (c) 2010 AACR.

Entities:  

Mesh:

Year:  2010        PMID: 20542985      PMCID: PMC3168562          DOI: 10.1158/1078-0432.CCR-10-0735

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

1.  The pediatric preclinical testing program: description of models and early testing results.

Authors:  Peter J Houghton; Christopher L Morton; Chandra Tucker; Debbie Payne; Edward Favours; Claire Cole; Richard Gorlick; E Anders Kolb; Wendong Zhang; Richard Lock; Hernan Carol; Mimi Tajbakhsh; C Patrick Reynolds; John M Maris; Joshua Courtright; Stephen T Keir; Henry S Friedman; Charles Stopford; Joseph Zeidner; Jianrong Wu; Tiebin Liu; Catherine A Billups; Javed Khan; Sherry Ansher; Jian Zhang; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2007-12       Impact factor: 3.167

2.  SK-NEP-1 and Rh1 are Ewing family tumor lines.

Authors:  Malcolm A Smith; Christopher L Morton; Doris Phelps; Kevin Girtman; Geoffrey Neale; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2008-03       Impact factor: 3.167

3.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

4.  KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors.

Authors:  Antonio Pérez-Martínez; Wing Leung; Evangelina Muñoz; Rekha Iyengar; Manuel Ramírez; José Luis Vicario; Alvaro Lassaletta; Julián Sevilla; Marta González-Vicent; Luis Madero; Miguel Angel Díaz-Pérez
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

5.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.

Authors:  Hiroyuki Fujisaki; Harumi Kakuda; Noriko Shimasaki; Chihaya Imai; Jing Ma; Timothy Lockey; Paul Eldridge; Wing H Leung; Dario Campana
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

6.  Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group.

Authors:  Patrick J Leavey; Leo Mascarenhas; Neyssa Marina; Zhengjia Chen; Mark Krailo; James Miser; Ken Brown; Nancy Tarbell; Mark L Bernstein; Linda Granowetter; Mark Gebhardt; Holcombe E Grier
Journal:  Pediatr Blood Cancer       Date:  2008-09       Impact factor: 3.167

7.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.

Authors:  Odile Oberlin; Annie Rey; Elizabeth Lyden; Gianni Bisogno; Michael C G Stevens; William H Meyer; Modesto Carli; James R Anderson
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

8.  Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group.

Authors:  James S Miser; Robert E Goldsby; Zhengjia Chen; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila G Moore; Aaron R Rausen; Teresa J Vietti; Holcombe E Grier
Journal:  Pediatr Blood Cancer       Date:  2007-12       Impact factor: 3.167

9.  NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.

Authors:  Dirk H J Verhoeven; Alfons S K de Hooge; Esther C K Mooiman; Susy Justo Santos; Monique M ten Dam; Hans Gelderblom; Cornelis J M Melief; Pancras C W Hogendoorn; R Maarten Egeler; Maarten J D van Tol; Marco W Schilham; Arjan C Lankester
Journal:  Mol Immunol       Date:  2008-07-26       Impact factor: 4.407

10.  Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice.

Authors:  Roberta Castriconi; Alessandra Dondero; Michele Cilli; Emanuela Ognio; Annalisa Pezzolo; Barbara De Giovanni; Claudio Gambini; Vito Pistoia; Lorenzo Moretta; Alessandro Moretta; Maria Valeria Corrias
Journal:  Cancer Immunol Immunother       Date:  2007-04-11       Impact factor: 6.968

View more
  95 in total

1.  Natural killer cell engineering for cellular therapy of cancer.

Authors:  D R Shook; D Campana
Journal:  Tissue Antigens       Date:  2011-12

Review 2.  Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas.

Authors:  Anish Ray; Winston W Huh
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

3.  Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Authors:  Sareetha Kailayangiri; Bianca Altvater; Christian Spurny; Silke Jamitzky; Sonja Schelhaas; Andreas H Jacobs; Constanze Wiek; Katharina Roellecke; Helmut Hanenberg; Wolfgang Hartmann; Heinz Wiendl; Susann Pankratz; Jutta Meltzer; Nicole Farwick; Lea Greune; Maike Fluegge; Claudia Rossig
Journal:  Oncoimmunology       Date:  2016-10-28       Impact factor: 8.110

4.  The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.

Authors:  Shiguo Zhu; Cecele J Denman; Zehra S Cobanoglu; Simin Kiany; Ching C Lau; Stephen M Gottschalk; Dennis P M Hughes; Eugenie S Kleinerman; Dean A Lee
Journal:  Pharm Res       Date:  2013-11-08       Impact factor: 4.200

Review 5.  Molecular mechanisms of natural killer cell activation in response to cellular stress.

Authors:  C J Chan; M J Smyth; L Martinet
Journal:  Cell Death Differ       Date:  2013-04-12       Impact factor: 15.828

6.  New strategies in ewing sarcoma: lost in translation?

Authors:  Fernanda I Arnaldez; Lee J Helman
Journal:  Clin Cancer Res       Date:  2014-04-22       Impact factor: 12.531

7.  Hemacytotoxicity and natural killer lytic index: New parameters to evaluate natural killer cell immunity for clinical use in cancer.

Authors:  Hyung Gun Maeng; Su Jin Lee; Yun A Lee; Hye Jeong Lee; Young Joo Kim; Jong Kyun Lee; Jae Cheol Kim; Joungbum Choi
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

Review 8.  Potential of human γδ T cells for immunotherapy of osteosarcoma.

Authors:  Zhaoxu Li
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

9.  Current therapeutic approaches in metastatic and recurrent ewing sarcoma.

Authors:  Michael Huang; Kenneth Lucas
Journal:  Sarcoma       Date:  2010-12-01

10.  Targeted Therapy of Ewing's Sarcoma.

Authors:  Vivek Subbiah; Pete Anderson
Journal:  Sarcoma       Date:  2010-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.